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A B S T R A C T
Isorhamnetin is one of the most important active ingredients in the fruits of Hippophae rhamnoides L. and the
leaves of Ginkgo biloba L., which possesses extensive pharmacological activities. At present, there have been
numerous investigations on isorhamnetin, which has the effects of cardiovascular and cerebrovascular protec-
tion, anti-tumor, anti-inflammatory, anti-oxidation, organ protection, prevention of obesity, etc. The related
mechanisms involve the regulation of PI3K/AKT/PKB, NF-κB, MAPK and other signaling pathways as well as the
expression of related cytokines and kinases. Isorhamnetin has a high value of development and application.
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⁎ Corresponding authors at: Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No. 1200, Cailun
Road, Shanghai, 200032, PR China.
⁎⁎ Corresponding author at: Acupuncture and Moxibustion Techniques Department, School of Acupuncture-moxibustion and Tuina, Shanghai University of
Traditional Chinese Medicine, No. 1200, Cailun Road, Shanghai 200032, PR China.
E-mail addresses: zhoushuang8008@163.com (S. Zhou), luanxin@shutcm.edu.cn (X. Luan), hqzhang51@126.com (H. Zhang).
1 These authors contributed equally to this work.
Biomedicine & Pharmacotherapy 128 (2020) 110301
0753-3322/ © 2020 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
However, the investigations on its mechanism of action are limited and lack of detailed scientific validation. The
manuscript reviewed the pharmacological effects of isorhamnetin and related mechanisms of action for the
development of its medicinal properties further.
1. Introduction
Over the last few years, the use of plant-derived drugs has risen
significantly in the therapeutic field. There are about 4000 flavonoids in
plants, many of which display medicinal properties [1]. Isorhamnetin, a
flavonoid compound, is present in the leaves, flowers and fruits of
Hippophae rhamnoides L. (Fig. 1), Ginkgo biloba L. (Fig. 2) and other
plants [2]. The fruits of Hippophae rhamnoides have the traditional ef-
ficacy of invigorating the spleen and eliminating food, relieving cough
and phlegm, promoting blood circulation and removing blood stasis.
The leaves of Ginkgo biloba possess the traditional efficacy of activating
blood circulation and removing blood stasis, dredging collaterals and
relieving pain, astringing the lung and relieving asthma, and reducing
turbidity and lipid. Isorhamnetin is one of the most important active
ingredients in the fruits of Hippophae rhamnoides and the leaves of
Ginkgo biloba. Fig. 3 displays the chemical structure of Isorhamnetin,
which has a wide spectrum of pharmacological effects, including car-
diovascular protection, anti-inflammation, anti-tumor, anti-oxidation,
anti-bacterial and anti-virus [2].
Studies have shown that isorhamnetin has a wide range of phar-
macological effects on cardiovascular diseases [3] and a variety of tu-
mors [4], and possesses the potential of preventing neurodegenerative
diseases [5] such as Alzheimer’s disease. It also has the pharmacody-
namics against hyperuricemia [6] and pulmonary fibrosis [7]. The
pharmacological effects of isorhamnetin are related to its regulation of
NF- κB, PI3K/ AKT, MAPK and other signaling pathways and their
downstream factors. The pharmacological action and mechanism of
isorhamnetin is currently a major research area.
It has been reported that isorhamnetin is cytotoxic to H9C2 cardi-
omyocytes [8] and mouse primary hepatocytes [9] and induces DNA
damage in HepG2 cells [10]. However, present studies on the tox-
icology of isorhamnetin are limited and further investigations are
warranted.
2. Cardio-cerebrovascular and nerve protection
Cardiovascular and cerebrovascular diseases are on the rise and
place significant economic burden on nations throughout the world.
Cardiovascular diseases tend to elicit more serious diseases. For ex-
ample, atherosclerosis leads to myocardial fibrosis and gradually de-
velops into heart failure. Isorhamnetin has a wide range of preventive
and therapeutic effects on cardiovascular and cerebrovascular diseases,
such as anti-atherosclerosis, protection of endothelial cells, anti-myo-
cardial ischemia, anti-hypotension, anti-hypoglycema, and anti-
thrombosis. The protective effects of isorhamnetin on the cardiovas-
cular system are almost related to antioxidation, anti-inflammation and
anti-apoptosis properties. In addition, isorhamnetin can also improve
nerve function, enhance cognition and memory, and prevent and treat
neurodegenerative disorders. Table 1 lists the effects of isorhamnetin on
cardiovascular and cerebrovascular and nervous system diseases. The
related mechanisms, experimental models and effective dosages are
also displayed in Table 1. Isorhamnetin can protect cardiovascular cells
against inflammation, oxidative damage and apoptosis by affecting
PI3K/AKT and NF-κB signaling pathways. Fig. 4 shows the mechanism
of action of isorhamnetin against cardiovascular and cerebrovascular
diseases.
2.1. Anti-atherosclerosis
Heme oxygenase (HO-1), an endogenous cytoprotective enzyme,
has anti-inflammation, anti-oxidative and anti-apoptotic effects and can
protect against atherosclerosis and other diseases [11]. The expression
of HO-1 is related to the activation of nuclear factor Nrf2 [12] which
binds to the antioxidant response element ARE in nuclei to increase the
expression of downstream antioxidant enzyme genes or proteins. The
PI3K/AKT pathway is related to Nrf2nuclear transcription [13]. The
phosphatidylinositol 3-kinases (PI3Ks) can regulate different cell func-
tions such as differentiation, proliferation, apoptosis, and glucose
transport. AKT, also named as protein kinase B (PKB) and the important
downstream effector of PI3K, can phosphorylate many downstream
factors such as enzymes, kinases and transcription factors to regulate
cell function [14]. The effect of isorhamnetin on P13 K/AKT pathway is
most probably dose-dependent. Yun et al. [15] reported that the sti-
mulation of oxidized low density lipoprotein raised the level of in-
tracellular ROS free radicals, and isorhamnetin at a concentration of
20mg/kg activated the P13 K/AKT pathway, increase the expression of
Nrf2/HO-1, reduced ROS levels and macrophage apoptosis, and in-
hibited the formation of atherosclerotic plaque in mice. However, the
investigation from Gao et al. [16] showed that the use of 100mg/kg/
day of isorhamnetin inhibited the PI3K/AKT signaling pathway and
reduced myocardial hypertrophy and fibrosis caused by pressure load.
Therefore, isorhamnetin also has the potential to prevent myocardial
hypertrophy, but the specific mechanism needs further validation.
Meanwhile, isorhamnetin has protective effects against H2O2 [8] and
hypoxia/ reoxygenation [17,18] -induced cardiomyocyte injury due to
the activation of Nrf2/HO-1 mediated oxidative signaling pathway, this
being mainly related to anti-oxidation and anti-apoptosis.
In addition, Chen et al. [19] found that isorhamnetin inhibited
vascular smooth muscle cells (VSMC) proliferation and collagen and
DNA synthesis in a dose-dependent manner. Phenotypic transforma-
tion, subintimal migration, proliferation and collagen synthesis of
VSMC are the basic pathological characteristics of atherosclerosis. Iso-
rhamnetin is probably useful for clinical prevention and treatment of
atherosclerosis.
2.2. Endothelial protection
Isorhamnetin exerts protective effects on endothelial cell injury
caused by H2O2 [20,21] and ox-LDL [22] owing to its effects of anti-
inflammation, anti-oxidation and anti-mitochondria-dependent apop-
tosis [23]. Isorhamnetin can inhibit the release of calcium from IP3
sensitive calcium pool to protect human umbilical vein endothelial cells
from the damage elicited by H2O2 promoting intracellular calcium
Fig. 1. Hippophae rhamnoides L.
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release [21]. Caspase-3 possesses an irreplaceable role in apoptosis as
the most important terminal cleavage enzyme. NO is an important
substance released by vascular endothelial cells and is involved in en-
dothelial dysfunction and apoptosis. The protective effect of iso-
rhamnetin on ox-LDL induced apoptosis in endothelial cells is related to
the inhibition of ox-LDL receptor 1 and Caspase-3 mRNA upreguation
and the decrease in NO release [22].
Fas and its ligand FasL are membrane surface molecules involved in
apoptosis. NF-κB, belonging to transcription factor family, can regulate
many molecules related to the early stage of immune response and
various stages of inflammatory response. Isorhamnetin can protect
cerebrovascular endothelial cells, inhibit FAS/FASL expression and NF-
κB translocation, and suppress Fas-mediated apoptosis and cell DNA
damage. It may be used in the treatment of cerebrovascular diseases
elicited by hyperglycemia and local ischemia [23].
2.3. Anti-myocardial ischemia
Ischemic injury of ventricular myocytes is a common cardiovascular
disease and ischemic myocardial reperfusion is widely used to rescue
injured tissues. However, it also leads to irreversible myocardial da-
mage. Isorhamnetin can alleviate the damage of Ischemia/reperfusion
to ventricular myocytes by inhibition of lactate dehydrogenase (LDH)
-elicited apoptosis via NF-κB signaling pathway [24].
2.4. Anti-myocardial fibrosis
Myocardial fibrosis is an important cause of heart failure and in-
volves cardiac fibroblast (CFb) proliferation and extracellular matrix
deposition. AngII is a growth regulator of CFb and can combine with the
receptor in CFb to promote CFb proliferation and the extracellular
matrix synthesis. Isorhamnetin inhibits the proliferation of CFb and
collagen synthesis induced by AngII in a concentration-dependent
manner, thus preventing myocardial fibrosis [25]. TGF-β is a cytokine
that adjusts cell differentiation, proliferation, apoptosis and extra-
cellular matrix synthesis. Smad is involved in intracellular TGF-β
signaling and isorhamnetin can alleviate myocardial collagen ag-
gregation and fibrosis in diabetic rats through repressing the TGF-β/
Smad signaling pathway [26].
2.5. Anti-cerebral ischemic injury
In the filament model of middle cerebral artery reperfusion in ex-
perimental stroke mice, isorhamnetin can reduce the infarct volume,
improve nerve function and protect the brain from ischemic injury.
Therefore, isorhamnetin could be used for the treatment of ischemic
stroke [27]. However, the specific mechanism of action is still unclear
and further experimental verification is needed.
2.6. Neuroprotection and improvement of memory and cognition
Isorhamnetin can be used as a potential medicine for the prevention
and treatment of various neurodegenerative disorders. Isorhamnetin
potentiates the nerve growth factor- induced neurite outgrowth [28].
Amyloid β-protein (Aβ) can be secreted by a variety of cells and has
strong neurotoxicity after precipitation and accumulation of cell matrix.
Besides causing neurodegenerative diseases, Aβ also leads to the de-
struction of blood-brain barrier. Isorhamnetin can destroy the stability
of Aβ aggregates, protect cells from Aβ-induced cytotoxicity and re-
verse the cell morphological changes induced by Aβ in human neuro-
blastoma SH-SY5Y cells. Thus isorhamnetin has a potential to prevent
the initiation of Alzheimer’s disease (AD) [29].
The open field test and morris water maze test indicate that iso-
rhamnetin can improve the spatial and non-spatial learning and
memory impairment induced by scopolamine. These effects are asso-
ciated with enhanced antioxidant defense systems, cholinergic sig-
naling, and synaptic plasticity by isorhamnetin [5]. It also enhances the
antioxidant defense system by increasing the activity of antioxidants in
the prefrontal cortex and hippocampus. In addition, isorhamnetin can
attenuate scopolamine-induced activity of cholinesterase and brain-
derived neurotrophic factor (BDNF) in the prefrontal cortex and hip-
pocampus to enhance cholinergic signaling and synaptic plasticity.
Isorhamnetin also decreases the activity of acetylcholinesterase [30].
Therefore, isorhamnetin can be developed as an anti-acet-
ylcholinesterase reagent to prevent neurodegenerative diseases. The
enhancing effect of isorhamnetin on cholinergic signal transduction is a
primary mechanism for the prevention and treatment of neurodegen-
erative diseases.
2.7. Hypotensive action
Hypertension is one of the important diseases threatening human
health, which could cause serious damage and pathological changes of
heart, brain and other organs. Isorhamnetin has the effect of lowering
blood pressure and selectivity to resistance vessel and the vasodilation
effect is inversely proportional to the diameter of the vessel studied
[31]. Hypertensive patients have disorders of cellular calcium regula-
tion, and Li et al. [32] found that isorhamnetin had double inhibitory
effects on voltage-dependent calcium channel (VDC) and receptor-op-
erated calcium channels (ROC) of vascular smooth muscle cells (VSMC)
in rabbits. It reduced intracellular free calcium level, thereby relaxing
blood vessels and lowering blood pressure. Zhu et al. [33] found that
isorhamnetin inhibited the increase of intracellular calcium con-
centration in vascular smooth muscle cells induced by potassium
chloride and norepinephrine in spontaneously hypertensive rats and
Wistar-Kyoto rats. Isorhamnetin might decrease the levels of Ca2+ in
VSMCs through blockage of both VDC and ROC in physiological or
pathological state, which is probably one of the mechanisms for its
hypotensive effects.
Isorhamnetin has endothelium-independent vasodilator effects in
aorta, mesenteric arteries and portal vein of rats and coronary arteries
of pigs. Isorhamnetin can also induce a positive inotropic effect in
Fig. 2. Ginkgo biloba L.
Fig. 3. Chemical structure of isorhamnetin.
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isolated atria of rats [34]. It has a dose-dependent vasodilative effect on
thoracic aortic rings. Low-dose isorhamnetin causes vasodilation
through the endothelium-dependent pathway, but this vasodilative ef-
fect at high-dose is independent of endothelium pathway. The vasodi-
lative mechanism of isorhamnetin may be related to endothelial NO/
GC/cGMP pathway and cyclooxygenase pathway. Promoting en-
dothelial NO production and activating cyclooxygenase increase the
production of PGI2, thus exerting vasodilator effect which is irrelevant
to ATP-activated potassium channel [35]. Therefore, the hypotensive
mechanism of isorhamnetin is mainly endothelium and non-en-
dothelium dependent. At high concentration, non-endothelium-depen-
dent inhibition of calcium channels reduces intracellular calcium levels,
but the low concentration promotes endothelial production of NO and
activation of COX, thereby relaxing blood vessels and resisting hy-
pertension.
2.8. Anti-thrombus
The formation of thrombus is related to vascular intimal injury,
blood properties and blood flow changes. The current primary treat-
ment strategy is to use thrombolytic drugs, antiplatelet drugs, and an-
ticoagulants. Ingesting onion soup rich in isorhamnetin can inhibit
collagen-stimulated platelet aggregation and some aspects of signal
transduction in vitro in a time-dependent manner, reducing the risk of
thrombosis [36]. Isorhamnetin can inhibit platelet aggregation caused
by either adenosine diphosphate (ADP) or platelet activating factor
(PAF) [37]. Therefore, isorhamnetin has the potential to be an anti-
platelet medicine for the treatment of thrombus.
2.9. Hypoglycemic effect
Hyperglycemia is also one of the most common diseases in modern
society. Sil et al. [38] found that when streptozotocin-induced diabetic
rats were administered isorhamnetin-3-O-beta-dextran complex at a
dose of 25mg/kg orally, serum glucose concentration and sorbitol ac-
cumulation were significant decreased in the lenses, red blood cells
(RBC) and sciatic nerves. Isorhamnetin is indicated for the prevention
and treatment of diabetes and its complications. Glucose transporter
type 4 (GLUT-4) is a membrane protein that exists only in insulin-
sensitive skeletal muscle, myocardium and adipocytes. After stimula-
tion by insulin, GLUT-4 can be transported from stored vesicles to the
outer membrane, bind to glucose and transported to cells. It plays an
important role in maintaining the body's blood glucose balance. Tyr-
osine kinase JAK/transcription factor STAT signaling pathway is a
signal transduction pathway activated by cytokines, which is relative to
cell proliferation, differentiation, apoptosis, and immune regulation. It
is also involved in inducing GLUT 4 translocation and maintaining
glucose homeostasis [39]. Isorhamnetin activates the JAK2/ STAT
pathway and promotes glucose uptake by increasing GLUT4 translo-
cation in different signaling pathways in skeletal muscle cells at a low
concentration range, thereby providing beneficial functions for pre-
venting hyperglycemia and maintaining glucose homeostasis [40].
Isorhamnetin might be developed as a hypoglycemic drug for the
treatment of hyperglycemia and related diseases.
3. Anti-tumor
Isorhamnetin displays a wide anti-tumor activity, which can inhibit
human cervical cancer cells [41,42], lung cancer cells [43–45], colon
cancer cells [46,47], breast cancer cells [48–50], pancreatic cancer cells
[51], nasopharyngeal cancer cells [52], liver cancer cells [53], gastric
cancer cells [54] and other cancer cells. Isorhamnetin inhibits the
proliferation of tumor cells, induces apoptosis, and regulates tumor
suppressor genes, proto-Oncogenes and signal pathways [4]. Table 2
lists the anti-tumor effects and mechanism of action for isorhamnetin.
Fig. 5 shows the anti-tumor mechanism of isorhamnetin.Ta
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MAPKs are a class of serine/threonine protein kinases in cells in-
volved in parallel signaling pathways. ERK, P38, JNK and MEK are
downstream factors. ERK is the key to the transmission of signals from
surface receptors to the nucleus and is involved in many biological
reactions such as cell proliferation and differentiation, apoptosis. RAS is
its upstream regulatory protein. It has been shown that isorhamnetin
can induce cell cycle arrest in G1 phase, decrease the phosphorylation of
cell proliferation pathway proteins AKT and ERK and the expression of
proliferating nuclear antigen Ki67, reduce Bcl-2 expression, increase
Bax expression, and promote the shear of Caspase 3, inducing apoptosis
[50]. Isorhamnetin exerts antitumor effect in breast cancer by reg-
ulating Akt and MEK signal transduction pathways [49]. Wang et al.
[51] found that isorhamnetin reduced the phosphorylation of MEK and
ERK in the Ras/ MAPK pathway, regulated cell proliferation, differ-
entiation and apoptosis in advanced pancreatic cancer cell line PANC-1.
Isorhamnetin may be a potential drug to prevent pancreatic cancer.
Jiang et al. [53] found that isorhamnetin blocked cells in G0-G1 phase,
prevented cells from entering S phase of DNA synthesis, and ultimately
suppressed the proliferation of HepG-2 cells in vitro.
Ataxia-telangiectasia mutation (ATM), a kinase that is activated in
the presence of a cellular injury signal, activates the checkpoint effector
kinase CHK2 to induce cell cycle arrest [55]. Isorhamnetin can arrest
the cell cycle in G2 / M phase, thus inhibiting cell proliferation of HeLa
cells, the mechanism of which is closely related to the activation of
ATM-CHK2 pathway and the destruction of microtubule function [42].
Isorhamnetin restrains the proliferation and colony formation of human
lung cancer cells (A549) and induces A549 cells apoptosis. The induc-
tion of apoptosis may be related to mitochondrial dependent pathway.
Through reducing mitochondrial membrane potential, isorhamnetin
promotes the release and activation of cytochrome c and caspase and
then induces A549 cells apoptosis [45,56]. Isorhamnetin also induces
apoptosis by down-regulating carcinogenic genes and upregulating
apoptotic genes, hence playing an important anti-tumor role [56].
Isorhamnetin can inhibit the growth of drug-resistant human lung
cancer cell lines (PC9-IR) by decreasing the phosphorylation level of
Akt473 [43]. Liu et al. [57] found that the antitumor effect of iso-
rhamnetin was also related to the induction of autophagy. In addition,
isorhamnetin can inhibit the growth of HeLa cells by inhibiting the
activity of telomerase [58].
Cytotoxic effect is an important mechanism for anti-tumor drugs.
Dong et al. [8] found that isorhamnetin was cytotoxic to H9C2 cardi-
omyocytes at the concentration of 80 μmol/L. After incubation of iso-
rhamnetin (30, 100, 300 μmol/L) with rat primary hepatocytes for 24 h,
the contents of AST, ALT and LDH in the culture medium were in-
creased, indicating that isorhamnetin possibly caused hepatocyte injury
[9]. In addition, Ginkgo biloba leaf extract has been shown to increase
the incidence of liver cancer in mice. In order to study the potential
carcinogenic mechanism, the human hepatoma cell line HepG2 was
used for experiments. It was found that isorhamnetin caused DNA da-
mage and this effect was related to the inhibition of topoisomerase II
[10].
In brief, isorhamnetin exerts anti-cancer effects mainly through
down-regulating Bcl-2 gene, up-regulating Bax gene, inhibiting telo-
mere activity, decreasing the expression of related proteins to block cell
cycle, depressing proliferation and inducing apoptosis.
4. Anti-inflammation
Isorhamnetin has anti-inflammatory effects on many diseases, such
as osteoarthritis and periodontitis, which can inhibit inflammatory re-
actions. In addition, the anti-inflammatory activity of isorhamnetin also
plays a role in anti-acute lung injury [59–61], anti-tuberculosis [62]
and kidney protection [63,64]. The mechanism is related to regulate
the production of inflammatory mediators, cytokines and ROS. Table 3
listed the anti-inflammatory effect and mechanism for isorhamnetin.
Some studies have shown that isorhamnetin has a protective effect on
LPS-induced acute lung injury model [59,60]. Chi et al. [59] found that
isorhamnetin inhibited the phosphorylation of ERK, JNK, IκBa and NF-
κB (p65) activated by LPS in vivo through affecting the signaling
pathways of MAPK and NF-κB and alleviated neutrophil infiltration and
edema in ALI model. Isorhamnetin could protect mice from LPS-in-
duced ALI by repressing the expression of COX-2 and suppress LPS-
induced inflammation in human gum fibroblasts by activating Nrf2
signaling pathway [65].
The human progestational hormone X receptor (PXR) is a known
target for abrogating inflammation in inflammatory bowel disease
(IBD) and isorhamnetin is an activator of human progesterone X re-
ceptor, which improves the experimental IBD through PXR-mediated
up-regulation of xenobiotic metabolism and down-regulation of NF-κB
signaling [66]. Kim et al. [67] found that isorhamnetin inhibited LPS-
mediated inflammation in BV2 microglia by inactivating NF-κB sig-
naling pathway, antagonizing TLR4 and eliminating ROS accumulation.
Isorhamnetin may have potential benefits in inhibiting the onset and
treatment of neuroinflammatory diseases. In addition, isorhamnetin has
a therapeutic effect on osteoarthritis. It has also shown that iso-
rhamnetin has anti-inflammatory and cartilage protective effects in IL1
β-stimulated cartilage cells [68]. Isorhamnetin inhibits RANKL-induced
osteoclast formation and protects chondrocytes from ROS damage by
regulating ROS [69]. It exerts anti-inflammatory effects by inhibition of
NF-κB signaling pathway and reduction of inflammatory factors release
and ROS production [61].
In conclusion, NF-κB pathway plays an extremely important role in
Fig. 4. Mechanism of action of isorhamnetin
against cardiovascular and cerebrovascular
diseases. According to the figure, it is known
that isorhamnetin plays a role in cardiovas-
cular and cerebrovascular diseases by reg-
ulating different signal pathways such as PI3K/
AKT. (↑: Hints activation or upregulation; ⊥:
Hints inhibition or downregulation.).
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anti-inflammatory effect of isorhamnetin. Many molecules in all stages
of inflammatory response are regulated by NF-κB, including TNF- α, IL-
1β, IL-2, IL-6, IL-8, IL-12, iNOS, COX2, chemokines, adhesion mole-
cules, colony stimulating factors plus others. Inhibition of NF-κB
pathway is the main anti-inflammatory mechanism of isorhamnetin.
5. Kidney protection
Isorhamnetin has a protective effect on AKI induced IR injury in
rats. The mechanism is related to inhibit over-activation of NF-κB sig-
naling pathway, alleviating inflammation and oxidative stress, so it can
be used in prevention and treatment of AKI in acute renal injury [63].
Isorhamnetin can ameliorate diabetes-elicited renal damage, which
may be relevant to the negative regulation of NF-κB pathway [64].
Isorhamnetin can inhibit the downstream inflammatory factors ex-
pression and the inflammatory response through the negative regula-
tion of NF-κB pathway, exerting a renal protective effect. The renal
protective effect and mechanism of isorhamnetin are shown in Table 3.
6. Lung protection
6.1. Anti-pulmonary fibrosis
Pulmonary fibrosis is a chronic and progressive disease character-
ized by alveolar epithelial injury and abnormal collagen production.
The pulmonary fibrosis model of C57 mice was established by in-
traperitoneal injection of a single dose of bleomycin (3.5U/kg), fol-
lowed by intragastric administration of isorhamnetin. The results
showed that isorhamnetin inhibited collagen deposition induced by
bleomycin, reduced the expression of type I collagen and alpha SMA,
and alleviated epithelial mesenchymal transformation (EMT) and en-
doplasmic reticulum stress (ERS) in vivo. Therefore isorhamnetin can be
used to inhibit EMT and pulmonary fibrosis induced by bleomycin [7].
Moreover, isorhamnetin can inhibit Ca2+ overload, reduce the pro-
duction of ROS and inhibit apoptosis through protein kinase C ε (PKCε)
pathway to decrease the damage induced by ERS [70]. The anti-pul-
monary fibrosis effect and mechanism of isorhamnetin are shown in
Table 4.
6.2. Anti-tuberculosis
Tuberculosis is a chronic infectious disease elicited by
Mycobacterium tuberculosis. Mycobacterium mainly causes strong local
inflammation in the lungs, which is essential in the pathogenesis of
tuberculosis, and isorhamnetin can inhibit the release of TNF-α and IL-
12. Meanwhile, isorhamnetin can decrease the stimulation of IFN-
gamma-mediated extracellular signal-regulated kinase and p38 MAPK,
and reduce the expression of TNF-α, IL-1β, IL-6, IL-12 and MMP-1 in
cells stimulated by IFN-γ, thus inhibiting the inflammatory response
[62]. Isorhamnetin can be used as an effective antituberculosis drug
due to its anti-inflammatory effect (as shown in Table 3).
7. Anti-osteoporosis
Osteoporosis is a systemic bone metabolic disease marked by low
bone mass and bone microstructure destruction, which is one of the
serious threats to the elderly and women's health. Isorhamnetin effec-
tively inhibits osteoclastogenesis and bone resorption in rat femoral
shaft and tendon tissue and mouse bone marrow cells to prevent os-
teoporosis [71], but the involved mechanism of action still remains
unclear. Chao et al. [72] performed bilateral ovariectomy in rats to
construct a model of women postmenopausal osteoporosis (PMOP) for
investigating the preventive and therapeutic effects of isorhamnetin on
PMOP. RANK ligand (RANKL) was detected in osteoblasts and bone
marrow stromal cells. The combination of NF-κB (RANK) receptor ac-
tivator with RANKL could promote the differentiation and activation of
osteoclasts. Osteoblasts and bone marrow stromal cells also express
osteoprotegerin OPG, which competes with RANK for binding to
RANKL, blocks the induction of osteoclasts and inhibits bone resorp-
tion. NFATc1 is a downstream factor of RANK signaling, which pro-
motes the expression of osteoclast-specific genes against tartrate acid
phosphatase TRAP and calcitonin receptor, leading to terminal differ-
entiation of osteoclasts. Isorhamnetin promotes osteoprotegerin OPG
expression in bone tissue, inhibits RANK/RANKL signaling pathway
activation, thereby reducing the expression of NFATc1 resulting in a
decrease in TRAP and osteocalcin (OC) expression. This regulates the
function of osteoblasts and osteoclasts, inhibits bone destruction and
improves bone microstructural damage in ovariectomized rats. Thus
isorhamnetin can be used in the prevention and treatment of osteo-
porosis. Li et al. [73] found that isorhamnetin could inhibit the differ-
entiation of RAW264.7 cells into osteoclasts and the mechanism was
related to inhibition of the classical NF-κB pathway. The NF-κB pathway
may be the main one by which isorhamnetin inhibits bone destruction
and displays anti-osteoporosis properties. The anti-osteoporosis effect
and mechanism of isorhamnetin are shown in Table 4.
Fig. 5. The anti-tumor mechanism of isorhamnetin. Isorhamnetin inhibits tumor cell proliferation and promotes apoptosis by regulating the expression of tumor-
related genes or proteins such as Bcl-2 and Bax.
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8. Anti-oxidation
Isorhamnetin can scavenge DPPH radical and ABTS radical and in-
hibit lipid peroxide of liver mitochondria in vitro, showing an anti-
oxidant activity [74]. Isorhamnetin has a potential protective effect
against oxidative stress in human RPE cells, and the mechanism of
action is related to the activation of PI3K/Akt signal transduction
pathway. Thus, it may be considered as a potential antioxidant for the
prevention of age related macular degeneration [75]. Isorhamnetin can
affect mitochondrial apoptosis pathway and activate Nrf2/ ARE sig-
naling pathway to realize antioxidant and anti-apoptotic functions,
protecting rat cardiomyocytes (H9C2) from hydrogen peroxide damage
[8]. Isorhamnetin can strengthen the cellular antioxidant defense ca-
pacity by activation of the Nrf2/ HO-1 and ERK pathways, thus pre-
venting C2C12 cells from H2O2-induced cytotoxicity [76]. Seo et al.
[77] found that isorhamnetin inhibited the migration and invasion of
cancer cells in vitro through inhibition of HIF-1α. Isorhamnetin also has
an antioxidant effect on linoleic acid peroxide induced by Gu2+ and
H2O2 [78]. These suggest that the anti-cancer effect of isorhamnetin is
relevant to anti-oxidation.
Kong et al. [79] evaluated the inhibitory effect of isorhamnetin 3-O-
β-D-glucopyranoside on oxidative stress in free cells and cell systems. It
not only exhibited dose-dependent scavenging activities on the gen-
eration of DPPH, hydroxyl and carbon-centered radicals, but also de-
creased the intracellular ROS level. It also increased the expression of
glutathione (GSH) and antioxidant enzymes, and suppressed the oxi-
dative damage of purified genomic DNA and the activity of MPO in
human bone marrow cells induced by TNF-α. Isorhamnetin is possibly a
candidate worthy of being developed as a natural antioxidant. In ad-
dition, some studies have shown that isorhamnetin can inhibit the
oxidative modification of HDL [80,81], LDL [82] and VLDL [83] in-
duced by Cu2 +.
In a word, isorhamnetin displays antioxidant properties by acti-
vating PI3K/Akt signal transduction pathway and Nrf2/ ARE signal
transduction pathway to inhibit apoptosis (as shown in Table 4).
9. Effect on hepatocytes
AMPK, an AMP-dependent protein kinase, plays an important role
in the regulation of cellular energy homeostasis, which can be activated
by CAMKK2. Isorhamnetin inhibits ROS generation, mitochondrial
dysfunction and GSH decrease induced by arachidonic acid (AA) +iron
[84], suggesting that isorhamnetin is probably a potential candidate
drug for the prevention of liver disease (Table 4). Isorhamnetin re-
presses HSC activation through activating Nrf2-ARE signaling, in-
hibiting TGF-β-mediated ROS production, and subsequently suppres-
sing classical TGF-β/Smad signaling pathway. This leads to the
inhibition of fibrosis gene expression including α-SMA and PAI-1,
thereby exerting an inhibitory effect on HSC activation, and conse-
quently liver fibrosis is prevented [85].
P38 is a downstream factor of MAPKs signaling pathway, which can
inhibit the activation of toll-like receptors to regulate the mRNA levels
of PPARs, and PPAR-α is an isoform of PPARs, which is closely related
to cell apoptosis and autophagy [86]. Isorhamnetin can inhibit ConA-
induced acute fulminant hepatitis (AFH) in mice through inhibiting
apoptosis and autophagy via the mouse P38/PPAR-α pathway [87]. It
can decrease the content of MDA, increase the content of GSH, ehance
the activity of SOD and GSH-Px activity and lower the release of ALT
and AST, protecting the damage of human normal hepatocytes (LO2)
induced by paracetamol (APAP) [88]. However, the specific mechanism
of action is unclear and needs further research. Fig. 6 shows the pro-
tective mechanism of isorhamnetin on liver.
10. Anti-hypoxia
Jiang et al. [89] studied the effects of isorhamnetin on the survivalTa
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time of mice under different hypoxia conditions (as shown in Table 4).
Experimental animal models of atmospheric hypoxia, specific myo-
cardial hypoxia and sodium nitroso toxic hypoxia were established by
different methods. The results showed that isorhamnetin could sig-
nificantly prolong the survival time of normobaric hypoxia, specific
myocardial hypoxia and sodium nitroso toxic hypoxia in mice, in-
dicating that isorhamnetin can enhance the hypoxia tolerance activity
in animals. However, the mechanism of action needs verification fur-
ther.
11. Anti-hyperuricemia
Hyperuricemia is an important risk factor for gout, which not only
causes damage to renal function, but also induces cardiovascular and
cerebrovascular diseases, and is accompanied by serious complications.
Isorhamnetin can decrease the activity of xanthine oxidase (XO) and
inhibit the production of uric acid (UA) in a dose-dependent manner
without changing the expression of XO protein in the liver. These
findings demonstrate that isorhamnetin has a potent anti-hyperur-
icemic effect and may be a potential candidate for prevention and re-
mediation of hyperuricemia [6]. The anti-hyperuricemia effect of iso-
rhamnetin and involved mechanism are shown in Table 4.
12. Regulating immunity
Wang et al. [90] found that isorhamnetin, the main component of
Miaoyao Fanggan sachet (MFS), could enhance innate immunity when
they studied the effect of MFS on the response of the innate immune
system. Dendritic cells (DCs) are regarded as important targets for
immunosuppressive therapy because of their important role in linking
natural and adaptive immunity. Shi et al. [91] investigated the function
and mechanism of isorhamnetin on BMDCs including maturation,
phagocytosis, and trafficking. It was found that isorhamnetin effectively
inhibited the maturation of LPS-treated BMDCs by down regulation of
TNF-α, IL-6, IL-1beta and IL-12p70, up regulation of IL-10, and de-
pression of CD40, CD80, and CD86, but no effects on phagocytosis. In
addition, chemokines are a class of small molecule basic proteins whose
main function is the directional movement of chemotactic cells. Iso-
rhamnetin depressed the migration of LPS-treated BMDCs possibly
through inhibition of CCR7 expression. Isorhamnetin might be also a
potent immunosuppressive agent, which inhibited the activation and
transport of dendritic cells to reduce inflammatory responses. The effect
of isorhamnetin on immune regulation and involved mechanism are
shown in Table 4.
13. Anti-bacterial and anti-viral effects
Ahmed et al. [92] found isorhamnetin to be an effective antiviral
agent. In mice infected with the influenza A virus, isorhamnetin sig-
nificantly reduced lung virus titer by 2 folds, raised the survival rate
ranging from 70 to 80%, and decreased body weight loss by 25 %. The
methyl group located on the B ring of isorhamnetin may contribute to
its strong antiviral potency against influenza virus in comparison with
other flavonoids. This anti-influenza effect is related to the inhibition of
HA and NA gene expression, virus-induced autophagy, ROS production
and ERK phosphorylation. Jiang et al. [93] found that isorhamnetin was
able to downregulate the gene RNAIII encoding alpha-hemolysin (Hlα)
and inhibiting Hlα transcription. In a co-culture system for S. aureus
and lung cells, topical isorhamnetin treatment protected against cell
injury elicited by S. aureus. Isorhamnetin may be a leading compound
for the development of anti-virulence drugs against S. aureus infections
[93]. When investigating antibacterial activity mechanism of poly-
phenols, Bhattacharya et al. [94] found that isorhamnetin had the
ability to permeate bacterial cell membrane through oxidative stress,
indicating its potential antibacterial activity which was further con-
firmed by Habtamu and Melaku [95]. Although the mechanism ofTa
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action needs to be determined further. The anti-bacterial and anti-viral
effects and mechanism of isorhamnetin are shown in Table 4.
14. Treatment of vitiligo
Vitiligo is a common acquired localized or generalized skin pig-
mentation disease and the current treatment is limited. Studies have
shown that all three PPAR subtypes are expressed in melanocytes,
which can promote melanin production [96]. The arachidonic acid
metabolic pathway and serotonin synapses are present in keratinocytes
and pigment cells, which promote the secretion of regulatory factors
such as PGE2, HETE and 5-HT. These regulators stimulate melanocyte
proliferation to produce melanin. Wang et al. [97] successfully pre-
dicted the melanogenic activity of isorhamnetin from Vernonia anthel-
mintica (L.) through admetSAR and SDTNBI methods of network
pharmacological analysis. It significantly increased the tyrosinase ac-
tivity, MITF protein expression and melanin-biosynthetic genes (MC1R,
MITF, TYR, TYRP1 and DCT) mRNA-expression. Based on the SDTNBI
method and experimental verification, isorhamnetin effectively in-
creased melanogenesis by targeting serotonergic synapses (ALOX12,
ALOX15) and pathways of MC1R-MITF, MAPK, PPAR (PPARA, PPARD,
PPARG), and arachidonic acid metabolism (ALOX12, ALOX15, CBR1)
(Table 4).
Fig. 6. Protective mechanism of isorhamnetin on liver. Isorhamnetin can protect the liver from many injuries such as autophagy and apoptosis by regulating a variety
of signal pathways.
Fig. 7. Obesity-preventing mechanism of isorhamnetin. Isorhamnetin can prevent obesity by inhibiting adipogenesis and promoting mitochondrial biogenesis.
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15. Prevention of obesity
César et al. [98] found that isorhamnetin extract from opuntia ficus-
indica (OFI) could reduce weight gain, increase insulin secretion and
energy consumption in mice fed with high-fat diet. This was eventually
responsible for the decrease of fat accumulation in liver and adipose
tissue, thus preventing hepatic steatosis and lipocyte hypertrophy.
Therefore, obesity may be prevented by ingestion of OFI containing
isorhamnetin (as shown in Table 4).
PPAR-γ activation may induce obesity and NAFLD. Isorhamnetin is
a novel antagonist of PPAR-γ, which suppresses the adipocyte differ-
entiation elicited by the PPAR-γ agonist rosiglitazone, obstructs obesity
development and alleviates hepatic steatosis caused by both high-fat
diet and leptin deficiency [99]. The molecular mechanism of action
involves isorhamnetin-mediated mitochondrial biogenesis and AMPK
activation in 3T3-L1 cells [100]. The mitochondrial biogenic effect of
isorhamnetin in adipocytes might be related to stimulation of mi-
tochondrial gene expression, mtDNA replication, and AMPK activation.
Fig. 7 shows the obesity-preventing mechanism of isorhamnetin.
16. Anti-ultraviolet injury
Han et al. [101] found that isorhamnetin eliminated ultraviolet
(UV) B-induced intracellular ROS and attenuated the oxidative mod-
ification of DNA, lipids and proteins in response to UVB radiation (as
shown in Table 4). Furthermore, it inhibited the programmed cell death
of keratinocytes promoted by UVB. Additionally, isorhamnetin in-
hibited mitochondrial dysfunction induced by UVB light, protecting
human keratinocytes from UVB-induced cell injury and death. Although
the effect is related to the antioxidant property of isorhamnetin, the
mechanism of action remains to be determined.
17. Conclusions and perspectives
Isorhamnetin has extensive pharmacological effects. Anti-osteo-
porosis, immune regulation and other pharmacological effects and the
involved mechanisms are shown in Table 4. The mechanisms of action
mainly involve anti-inflammation, antioxidation and regulation of
apoptosis. These pharmacological activities often play an important
role in the treatment of different diseases, such as the anti-oxidative and
anti-inflammatory effects of isorhamnetin on acute kidney injury and
acute fulminant hepatitis in mice. At the same time, isorhamnetin can
inhibit HIF-1α due to its antioxidant potential, thus inhibiting the mi-
gration and invasion of cancer cells in vitro. The multiple effects of
isorhamnetin play an important role in the treatment of diseases by
PI3K/AKT, NF-κB and other signaling pathways and cytokines, dis-
playing a high medicinal value.
However, this review points out some limitations of the pharma-
cological research on isorhamnetin. i) At present, there are many in vitro
investigations on isorhamnetin, but relatively few in vivo studies; ii) The
toxicological study is insufficient; iii) The mechanisms of anti-
hypertensive, antithrombotic, anti-hypoxia and anti-ultraviolet damage
have not been elucidated; iiii) Few therapeutical targets are in-
vestigated for isorhamnetin, which of is great significance to clarify the
exact mechanism of action of isorhamnetin.
In future, it is necessary to focus on the following aspects: i)
strengthening in vivo research, especially the effects on PI3K/ AKT, NF-
κB signaling pathways and cytokines, and further exploring the phar-
macological action and related molecular mechanism; ii) Strengthening
the study of toxicology and drug interactions of isorhamnetin to es-
tablish the safety characteristics of humans and promote the develop-
ment of medicinal value of isorhamnetin; iii) Strengthening the study
on pharmacological effects and structure-activity relationship of iso-
rhamnetin and its derivatives; iiii) Investigating the binding target for
pharmacological effects of isorhamnetin. Finally, it is hoped that fur-
ther research will address the concerns raised above to provide further
data so that isorhamnetin can be clinically used for the treatment of
diseases.
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